| Symbol | DTIL |
|---|---|
| Name | PRECISION BIOSCIENCES INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | 302 EAST PETTIGREW STREET, DURHAM, NC 27701 |
| Telephone | 919-314-5512 |
| Fax | — |
| — | |
| Website | https://www.precisionbiosciences.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001357874 |
| Description | Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The companys segments include Therapeutics and Food out of which the Therapeutics segment act as a key revenue driver for the firm. Additional info from NASDAQ: |
2026-05-05 11:19
(10% Negative) PRECISION BIOSCIENCES INC (DTIL) Reports Q2 2026 Financial Results
Read more
2026-05-05 11:01
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
Read more
2026-04-30 11:01
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
Read more
2026-04-29 11:01
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
Read more
2026-04-28 12:02
iECURE to Present Preliminary Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at the ASGCT and SIMD Annual Meetings
Read more
2026-04-28 11:01
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
Read more
2026-04-24 11:01
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read more
2026-04-22 11:01
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026
Read more
2026-04-15 11:01
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
Read more
2026-04-15 10:46
New Form SCHEDULE 13G/A - PRECISION BIOSCIENCES INC <b>Filed:</b> 2026-04-15 <b>AccNo:</b> 0000902664-26-001989 <b>Size:</b> 11 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06745258 | ICARE-LCS QUERI Partnered Evaluation Initiative: Integrating Comprehensive Toba… | — | Tobacco Dependence Treatment | Not_Yet_Recruiting | 2026-05-01 | 2027-06-30 | ClinicalTrials.gov |
| NCT07325578 | U.S. Prospective Evaluation of EPIONE Device for Percutaneous MSK Procedures | Na | Bone Tumor | Recruiting | 2026-04-28 | 2026-10-01 | ClinicalTrials.gov |
| NCT07429240 | PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscula… | Phase1 | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | Recruiting | 2026-04-24 | 2029-12-01 | ClinicalTrials.gov |
| NCT07346846 | A Study of BGM-2121 in Patients With Advanced Solid Tumors | Phase1 | Advanced Solid Tumors | Recruiting | 2026-03-10 | 2028-12-01 | ClinicalTrials.gov |
| NCT07456371 | PIC1 Injection Therapy for Relapsed/Refractory B-NHL | Phase1 | Non-Hodgkin Lymphoma | Recruiting | 2026-03-01 | 2029-02-01 | ClinicalTrials.gov |
| NCT07403097 | Study of CD19 CAR-T Therapy for Refractory SLE | Phase1 | Systemic Lupus Erythematosus | Recruiting | 2026-02-01 | 2028-12-01 | ClinicalTrials.gov |
| NCT07318259 | Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE | Phase1 | Systemic Lupus Erythematosus | Recruiting | 2026-01-26 | 2028-08-01 | ClinicalTrials.gov |
| NCT07254208 | A Long-term Observational Study in Participants Who Have Received PBGENE-HBV | — | Chronic HBV Infection | Enrolling_By_Invitation | 2025-12-25 | 2040-06-01 | ClinicalTrials.gov |
| NCT07247396 | CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Perito… | Phase1 | Peritoneal Metastases From Colorectal Cancer | Recruiting | 2025-11-03 | 2027-10-31 | ClinicalTrials.gov |
| NCT07161193 | Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases | Phase1 | Autoimmune Diseases | Not_Yet_Recruiting | 2025-09-30 | 2027-11-18 | ClinicalTrials.gov |
| NCT07181720 | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | Phase1 | Renal Cell Carcinoma (RCC) | Recruiting | 2025-09-12 | 2028-05-31 | ClinicalTrials.gov |
| NCT07184450 | Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rhe… | Phase1 | Juvenile Dermatomyositis (JDM) | Recruiting | 2025-09-01 | 2028-09-30 | ClinicalTrials.gov |
| NCT07040436 | Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patient… | Phase1 | Advanced Melanoma | Not_Yet_Recruiting | 2025-09-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT06362421 | Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pha… | — | Oropharyngeal Squamous Cell Carcinoma | Withdrawn | 2025-08-01 | 2026-08-01 | ClinicalTrials.gov |
| NCT07239323 | In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies | Phase1 | B-Acute Lymphoblastic Leukemia | Recruiting | 2025-07-01 | 2028-12-31 | ClinicalTrials.gov |
| NCT06892145 | Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE | Phase1 | Systemic Lupus Erythematosus (SLE) | Recruiting | 2025-06-12 | 2028-02-16 | ClinicalTrials.gov |
| NCT06992583 | Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer | Phase1 | Advanced Lung Cancer | Recruiting | 2025-05-08 | 2028-04-30 | ClinicalTrials.gov |
| NCT06945523 | Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA … | Phase1 | Advanced Lung Cancer | Recruiting | 2025-04-28 | 2028-04-30 | ClinicalTrials.gov |
| NCT06934447 | Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE | Phase1 | CAR T Cell Therapy | Recruiting | 2025-04-25 | 2028-04-01 | ClinicalTrials.gov |
| NCT07015801 | CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV … | Na | Cytomegalovirus Viremia | Active_Not_Recruiting | 2025-04-15 | 2040-04-01 | ClinicalTrials.gov |
| NCT06909474 | Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hem… | Phase1 | T-ALL/Lymphoma | Recruiting | 2025-03-27 | 2028-03-31 | ClinicalTrials.gov |
| NCT06903117 | Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma | Phase1 | Advanced Lung Cancer | Recruiting | 2025-03-24 | 2028-03-31 | ClinicalTrials.gov |
| NCT06813417 | CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part Sarcoma | Early_Phase1 | Sarcoma | Active_Not_Recruiting | 2025-01-30 | 2030-01-30 | ClinicalTrials.gov |
| NCT06789172 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With S… | Phase1 | Solid Tumours | Recruiting | 2025-01-23 | 2028-09-01 | ClinicalTrials.gov |
| NCT06723275 | LEOPARD Prospective Validation Cohort 1 | — | Decompensated Liver Cirrhosis | Not_Yet_Recruiting | 2025-01-01 | 2027-10-01 | ClinicalTrials.gov |
| NCT06768151 | A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer | Phase1 | Advanced Lung Cancer | Recruiting | 2024-12-12 | 2027-12-31 | ClinicalTrials.gov |
| NCT02546102 | Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma | Phase3 | Glioblastoma Multiforme | Suspended | 2024-12-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT06464510 | Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopres… | Phase3 | Septic Shock | Recruiting | 2024-11-21 | 2027-09-01 | ClinicalTrials.gov |
| NCT06680232 | Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult … | Phase1 | HEPATITIS B CHRONIC | Recruiting | 2024-11-14 | 2026-12-01 | ClinicalTrials.gov |
| NCT06690827 | Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or B… | Phase1 | AML (Acute Myeloid Leukemia) | Recruiting | 2024-11-13 | 2028-10-30 | ClinicalTrials.gov |
| NCT06686524 | Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocyt… | Phase1 | Dermatomyositis, Juvenile | Recruiting | 2024-11-11 | 2027-11-10 | ClinicalTrials.gov |
| NCT06641024 | Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL | Phase1 | Acute Lymphoblastic Leukemia, in Relapse | Not_Yet_Recruiting | 2024-11-01 | 2039-11-01 | ClinicalTrials.gov |
| NCT05848856 | The RISC Registry--Risk Informed Screening Registry | — | Breast Cancer Risk | Not_Yet_Recruiting | 2024-09-01 | 2035-09-01 | ClinicalTrials.gov |
| NCT06821048 | Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced … | Phase1 | Colorectal Cancer | Recruiting | 2024-07-24 | 2027-12-01 | ClinicalTrials.gov |
| NCT06222853 | Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic L… | Phase1 | Systemic Lupus Erythematosus | Active_Not_Recruiting | 2024-02-10 | 2026-12-30 | ClinicalTrials.gov |
| NCT06215950 | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive… | Phase1 | Ovarian Cancer | Recruiting | 2024-01-10 | 2027-12-31 | ClinicalTrials.gov |
| NCT06180174 | Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lym… | Phase1 | B Cell Lymphoma | Recruiting | 2023-12-31 | 2026-12-31 | ClinicalTrials.gov |
| NCT06010875 | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive… | Phase1 | Renal Cell Carcinoma | Recruiting | 2023-11-30 | 2026-09-30 | ClinicalTrials.gov |
| NCT06126406 | Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） … | Phase1 | Gastric Cancer | Recruiting | 2023-11-06 | 2026-12-31 | ClinicalTrials.gov |
| NCT06010862 | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastat… | Phase1 | Gastric Cancer | Recruiting | 2023-09-30 | 2026-09-30 | ClinicalTrials.gov |
| NCT06030999 | The Prevention And Treatment On Obesity And Weight Management By Oral Supplemen… | Na | Overweight and Obesity | Completed | 2023-09-18 | 2023-12-15 | ClinicalTrials.gov |
| NCT06006390 | CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment … | Phase1 | Gastric Cancer | Recruiting | 2023-09-07 | 2026-08-31 | ClinicalTrials.gov |
| NCT06056921 | Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Di… | Phase1 | SLE (Systemic Lupus) | Recruiting | 2023-08-31 | 2026-08-31 | ClinicalTrials.gov |
| NCT06006403 | Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myel… | Phase1 | Acute Myeloid Leukemia | Recruiting | 2023-08-31 | 2026-08-31 | ClinicalTrials.gov |
| NCT06043466 | A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Posi… | Phase1 | Colorectal Cancer | Recruiting | 2023-08-11 | 2027-12-31 | ClinicalTrials.gov |
| NCT05900752 | A Multi-Strain Probiotic Reduces the Frequency of Diarrhea in IBS-D Patients | Na | IBS - Irritable Bowel Syndrome | Completed | 2023-06-19 | 2023-07-16 | ClinicalTrials.gov |
| NCT05048407 | Sirius in Gynaecological Laparoscopic Surgery | Na | Ovarian Cancer | Unknown | 2023-05-30 | 2024-06-30 | ClinicalTrials.gov |
| NCT05756712 | The Efficacy of White Kidney Bean on Oral Glucose Tolerance Test | Na | Diabetes | Completed | 2023-03-06 | 2023-03-31 | ClinicalTrials.gov |
| NCT05696938 | Improved Skin Whitening Outcomes Associated With Nicotinamide Fortified Consump… | Na | Skin Darken | Completed | 2023-02-16 | 2023-04-26 | ClinicalTrials.gov |
| NCT05710055 | The Efficacy on Overweight With Oral Supplemenation of Probiotics and Prebiotics | Na | Overweight | Completed | 2023-02-06 | 2023-04-30 | ClinicalTrials.gov |
| NCT05682092 | Study of Collagen Efficacy on Skin Anti-aging in 30 to 50-Year-Old Women | Na | Skin Laxity | Completed | 2023-01-16 | 2023-03-31 | ClinicalTrials.gov |
| NCT05318625 | A Prospective Study to Evaluate the Clinical Performance and Safety of the SIRI… | Na | Ovarian Cancer | Unknown | 2023-01-10 | 2024-07-01 | ClinicalTrials.gov |
| NCT05585021 | Clinical Study on the Effect of Probiotic Compound Powder on the Immunity Impro… | Na | Immunity | Completed | 2022-10-19 | 2023-04-30 | ClinicalTrials.gov |
| NCT05517889 | Repeatability and Stability of Healthy Skin Features on OCT | — | Optical Coherence Tomography | Completed | 2022-09-01 | 2023-12-31 | ClinicalTrials.gov |
| NCT05468190 | A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treate… | Phase1 | Metastatic Tumor | Unknown | 2022-07-17 | 2025-07-17 | ClinicalTrials.gov |
| NCT05549921 | Phase II Study of TAEST16001 in Soft Tissue Sarcoma | Phase2 | Soft Tissue Sarcoma | Unknown | 2022-07-08 | 2024-09-01 | ClinicalTrials.gov |
| NCT05538195 | Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant S… | Phase1 | Gastric Cancer | Unknown | 2022-06-07 | 2025-06-07 | ClinicalTrials.gov |
| NCT05518253 | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advan… | Phase1 | Metastatic Tumor | Recruiting | 2022-05-30 | 2027-05-30 | ClinicalTrials.gov |
| NCT05396300 | A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advance… | Phase1 | Colorectal Cancer | Recruiting | 2022-05-25 | 2027-12-30 | ClinicalTrials.gov |
| NCT05351060 | Novel Splinting Technique Using 3D Models | Na | Arthritis | Unknown | 2022-05-16 | 2022-08-19 | ClinicalTrials.gov |
| NCT05414422 | A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Effic… | Phase2 | Treatment Resistant Depression | Completed | 2022-02-01 | 2022-11-10 | ClinicalTrials.gov |
| NCT05334823 | A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL… | Phase2 | Acute Lymphoblastic Leukemia | Recruiting | 2022-01-26 | 2025-07-01 | ClinicalTrials.gov |
| NCT05121090 | Lille Study for Childhood Health Promotion | — | Overweight, Infant | Active_Not_Recruiting | 2022-01-19 | 2027-04-01 | ClinicalTrials.gov |
| NCT05420545 | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advan… | Phase1 | Metastatic Tumor | Unknown | 2021-12-31 | 2024-12-31 | ClinicalTrials.gov |
| NCT05717491 | Study of Diabetes' Risk Factors and Accelerated Aging According to Socio-econom… | — | Diabetes | Completed | 2021-12-14 | 2024-03-31 | ClinicalTrials.gov |
| NCT04925440 | The Effects of Bifidobacterium Longum 1714® in a Population With Low Mood | Na | Low Mood | Completed | 2021-09-13 | 2022-08-19 | ClinicalTrials.gov |
| NCT05415475 | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignan… | Phase1 | Colorectal Cancer | Unknown | 2021-09-10 | 2025-09-15 | ClinicalTrials.gov |
| NCT05420493 | Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatm… | Phase1 | Relapsed Non-Hodgkin Lymphoma | Unknown | 2021-09-06 | 2025-09-30 | ClinicalTrials.gov |
| NCT04749433 | Study of [11C]CPPC to Assess the Safety and Tolerability in Patients With ALS | Phase1 | Amyotrophic Lateral Sclerosis | Terminated | 2021-09-01 | 2023-03-30 | ClinicalTrials.gov |
| NCT04586075 | UW Undiagnosed Genetic Diseases Program | — | Rare Diseases | Recruiting | 2021-07-16 | 2030-10-01 | ClinicalTrials.gov |
| NCT04649112 | Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressin… | Phase1 | CD19 Expressing Malignancies | Completed | 2021-06-16 | 2023-09-30 | ClinicalTrials.gov |
| NCT04861480 | Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multip… | Phase1 | Multiple Myeloma in Relapse | Unknown | 2021-06-16 | 2024-07-18 | ClinicalTrials.gov |
| NCT04782193 | a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refr… | Phase1 | B Cell Lymphoma | Unknown | 2021-05-23 | 2024-07-01 | ClinicalTrials.gov |
| NCT04765137 | Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cogni… | Phase2 | Mild Cognitive Impairment | Recruiting | 2021-05-21 | 2026-12-31 | ClinicalTrials.gov |
| NCT04843332 | Community Health Workers and Precision Medicine | Na | Cancer | Completed | 2021-05-03 | 2023-10-31 | ClinicalTrials.gov |
| NCT04499833 | HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocel… | Na | Hepatocellular Carcinoma, Scirrhous | Recruiting | 2021-03-25 | 2029-12-31 | ClinicalTrials.gov |
| NCT04776330 | a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refra… | Phase1 | Multiple Myeloma | Recruiting | 2021-03-07 | 2027-07-01 | ClinicalTrials.gov |
| NCT04781634 | a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refr… | Phase1 | B-ALL | Recruiting | 2021-03-07 | 2027-07-01 | ClinicalTrials.gov |
| NCT04815681 | Evaluating an Online Wellness Intervention for Greek Adolescents | Na | Depressive Symptoms | Withdrawn | 2021-03-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT04639739 | Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma. | Early_Phase1 | NHL | Unknown | 2020-12-17 | 2023-12-01 | ClinicalTrials.gov |
| NCT04616209 | Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patie… | Phase1 | Non-small Cell Lung Cancer | Recruiting | 2020-11-15 | 2027-12-31 | ClinicalTrials.gov |
| NCT04888442 | Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refr… | Phase1 | Acute Lymphoblastic Leukemia, in Relapse | Unknown | 2020-10-26 | 2022-03-28 | ClinicalTrials.gov |
| NCT04410133 | Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detect… | Phase3 | Brain Metastases | Completed | 2020-10-26 | 2023-06-05 | ClinicalTrials.gov |
| NCT04410367 | Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in De… | Phase2 | Brain Metastases | Completed | 2020-08-31 | 2021-12-31 | ClinicalTrials.gov |
| NCT04648475 | Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refrac… | Phase1 | Leukemia, B-cell | Unknown | 2020-08-25 | 2024-07-01 | ClinicalTrials.gov |
| NCT04334031 | Deployment o the Multidisciplinary Prospective Cohort Imminent | Na | Chronic Inflammatory Disease | Recruiting | 2020-07-20 | 2031-07-21 | ClinicalTrials.gov |
| NCT04171843 | A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR26… | Phase1 | Relapsed/Refractory Multiple Myeloma | Terminated | 2020-04-30 | 2022-10-19 | ClinicalTrials.gov |
| NCT04030195 | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL… | Phase1 | Non-Hodgkin's Lymphoma, Relapsed | Completed | 2020-03-24 | 2021-06-24 | ClinicalTrials.gov |
| NCT04318964 | TAEST16001 in the Treatment of Soft Tissue Sarcoma | Phase1 | Soft Tissue Sarcoma | Unknown | 2020-03-19 | 2024-05-01 | ClinicalTrials.gov |
| NCT04256395 | Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible I… | — | Susceptibility to Viral and Mycobacterial Infection | Completed | 2020-02-01 | 2020-07-01 | ClinicalTrials.gov |
| NCT04404010 | Virtual Reality vs Technical Video in Surgical Training | Na | Surgical Training | Completed | 2020-01-30 | 2020-02-01 | ClinicalTrials.gov |
| NCT04123470 | A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Ma… | Phase1 | Malignant Melanoma | Completed | 2020-01-28 | 2023-07-30 | ClinicalTrials.gov |
| NCT04167475 | Effect of B. Longum 1714™ on Sleep Quality | Phase2 | Subjective Sleep Quality | Completed | 2020-01-06 | 2020-06-23 | ClinicalTrials.gov |
| NCT04305093 | Data Mining: Precision Analytical Retrospective Data Correlation | — | Obesity; Endocrine | Completed | 2019-12-15 | 2023-03-28 | ClinicalTrials.gov |
| NCT04272125 | Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acu… | Phase1 | Leukemia | Unknown | 2019-12-01 | 2024-07-01 | ClinicalTrials.gov |
| NCT04272151 | Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Mult… | Phase1 | Multiple Myeloma | Unknown | 2019-12-01 | 2024-07-01 | ClinicalTrials.gov |
| NCT04271800 | Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19… | Phase1 | Leukemia | Unknown | 2019-12-01 | 2024-07-01 | ClinicalTrials.gov |
| NCT04888468 | Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory… | Phase1 | Acute Lymphoblastic Leukemia | Completed | 2019-11-05 | 2021-09-01 | ClinicalTrials.gov |
| NCT04649983 | CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukem… | Phase1 | Leukemia, B-cell | Unknown | 2019-09-01 | 2024-07-01 | ClinicalTrials.gov |
| NCT03957252 | Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of C… | — | Prostate Cancer | Active_Not_Recruiting | 2019-06-06 | 2027-03-01 | ClinicalTrials.gov |
| NCT04271410 | CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia … | Phase1 | Leukemia | Unknown | 2019-06-01 | 2024-07-01 | ClinicalTrials.gov |
| NCT03707431 | Internet Based Cognitive Behavioral Therapy in Pediatric Chronic Pancreatitis | Na | Chronic Pancreatitis | Completed | 2019-04-25 | 2024-07-31 | ClinicalTrials.gov |
| NCT04271644 | BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and P… | Phase1 | Multiple Myeloma | Recruiting | 2019-04-01 | 2027-07-01 | ClinicalTrials.gov |
| NCT03844191 | A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered R… | Phase1 | Coronary Disease | Completed | 2019-02-18 | 2019-12-01 | ClinicalTrials.gov |
| NCT03476681 | Study of NEO-201 in Solid Tumors Expansion Cohorts | Phase1 | Non Small Cell Lung Cancer | Recruiting | 2019-01-18 | 2029-01-15 | ClinicalTrials.gov |
| NCT07271446 | An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Trea… | Phase1 | Non-small Cell Lung Cancer | Completed | 2018-09-01 | 2023-12-01 | ClinicalTrials.gov |
| NCT03462316 | NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma | Phase1 | Bone Sarcoma | Unknown | 2018-05-21 | 2024-05-15 | ClinicalTrials.gov |
| NCT03504761 | ClariCore System Used in Transrectal Ultrasound Guided Prostate Biopsy for Real… | Na | Cellular Diagnosis, Prostate Cancer | Unknown | 2018-04-25 | 2020-12-01 | ClinicalTrials.gov |
| NCT03159585 | To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancin… | Phase1 | Liver Cancer Stage IV | Completed | 2017-04-14 | 2019-06-04 | ClinicalTrials.gov |
| NCT03029273 | NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC | Phase1 | Lung Cancer, Nonsmall Cell, Recurrent | Unknown | 2017-03-21 | 2019-03-01 | ClinicalTrials.gov |
| NCT03091101 | Impact of Scleral Contact Lens Wear on Corneal Nerves in Keratoconus | Na | Keratoconus | Completed | 2017-03-15 | 2018-03-21 | ClinicalTrials.gov |
| NCT03064360 | Early Prediction of Major Adverse Cardiovascular Events Using Remote Monitoring | — | Ischemic Heart Disease | Completed | 2017-02-13 | 2020-01-01 | ClinicalTrials.gov |
| NCT03158571 | Chilean Gastric Cancer Task Force (FORCE 1) | — | Biomarkers | Completed | 2017-01-01 | 2019-01-01 | ClinicalTrials.gov |
| NCT02514590 | Wireless Spinal Cord Stimulation for Chronic Pain | Na | Back Pain | Completed | 2016-07-01 | 2019-07-01 | ClinicalTrials.gov |
| NCT02910037 | Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort | Na | Encephalitis | Completed | 2016-06-01 | 2017-07-31 | ClinicalTrials.gov |
| NCT02773940 | ClariCore™ Biopsy System in Patients Undergoing Radical Retropubic Prostatectomy | Na | Prostate Cancer | Unknown | 2016-05-01 | 2020-06-01 | ClinicalTrials.gov |
| NCT03123757 | Assessing the Determinants of 6-minute Walk Test and Its Correlation With Quali… | Na | Aged | Completed | 2015-04-01 | 2015-08-31 | ClinicalTrials.gov |
| NCT02925741 | Silk-Like Bed Linens for Prevention of Unit-Acquired Ulcers | Na | Pressure Ulcer | Completed | 2014-03-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01834235 | QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C t… | Phase1 | Pancreatic Cancer, Adult | Terminated | 2013-04-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT01826461 | An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment o… | Phase2 | Atopic Dermatitis | Completed | 2013-03-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01040000 | QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Panc… | Phase1 | Metastatic Pancreatic Cancer | Completed | 2012-01-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01280552 | A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM) | Phase2 | Glioblastoma Multiforme | Completed | 2011-01-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01355666 | Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setti… | Na | Pressure Ulcers | Unknown | 2010-09-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01049126 | Retrospective Case Study Examining Patient Outcomes Compared to the ChemoFx Ass… | — | Endometrial Cancer | Completed | 2009-07-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00944216 | Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to S… | Phase4 | Keratosis Pilaris | Terminated | 2009-06-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00767104 | Efficacy of Silk - Like Bedding Fabric Pillow Case in the Treatment of Acne Vul… | Na | Acne Vulgaris | Completed | 2008-10-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00705185 | Exploring a Potential Blood Test to Diagnose Major Depressive Disorder | — | Major Depressive Disorder | Completed | 2008-04-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00669422 | ChemoFx® PRO - A Post-Market Data Collection Study | — | Ovarian Cancer | Terminated | 2006-10-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00782054 | Evaluation of Post Burn Rehabilitation Population for Itch Control | Phase4 | Pruritus | Completed | 2006-09-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00288275 | Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epit… | — | Ovarian Cancer | Terminated | 2004-07-01 | 2012-10-01 | ClinicalTrials.gov |
Total clinical trials: 130
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| SF-12 questionnaire | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Biobanking with genetic analysis | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Percutaneous procedure in the MSK structures of the pelvis and/or the spine | Procedure | Approved | Bone Tumor | RECRUITING | NCT07325578 |
| Percutaneous procedure in the MSK structures of the pelvis and/or the spine | Procedure | Approved | Bone Tumor | RECRUITING | NCT07325578 |
| SF-12 questionnaire | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Biobanking with genetic analysis | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Percutaneous procedure in the MSK structures of the pelvis and/or the spine | Procedure | Approved | Bone Tumor | RECRUITING | NCT07325578 |
| SF-12 questionnaire | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Biobanking with genetic analysis | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Percutaneous procedure in the MSK structures of the pelvis and/or the spine | Procedure | Approved | Bone Tumor | RECRUITING | NCT07325578 |
| SF-12 questionnaire | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Biobanking with genetic analysis | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Percutaneous procedure in the MSK structures of the pelvis and/or the spine | Procedure | Approved | Bone Tumor | RECRUITING | NCT07325578 |
| SF-12 questionnaire | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Biobanking with genetic analysis | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Percutaneous procedure in the MSK structures of the pelvis and/or the spine | Procedure | Approved | Bone Tumor | RECRUITING | NCT07325578 |
| SF-12 questionnaire | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Biobanking with genetic analysis | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Percutaneous procedure in the MSK structures of the pelvis and/or the spine | Procedure | Approved | Bone Tumor | RECRUITING | NCT07325578 |
| SF-12 questionnaire | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Biobanking with genetic analysis | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Percutaneous procedure in the MSK structures of the pelvis and/or the spine | Procedure | Approved | Bone Tumor | RECRUITING | NCT07325578 |
| SF-12 questionnaire | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Biobanking with genetic analysis | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Percutaneous procedure in the MSK structures of the pelvis and/or the spine | Procedure | Approved | Bone Tumor | RECRUITING | NCT07325578 |
| SF-12 questionnaire | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Biobanking with genetic analysis | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Percutaneous procedure in the MSK structures of the pelvis and/or the spine | Procedure | Approved | Bone Tumor | RECRUITING | NCT07325578 |
| SF-12 questionnaire | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Biobanking with genetic analysis | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Percutaneous procedure in the MSK structures of the pelvis and/or the spine | Procedure | Approved | Bone Tumor | RECRUITING | NCT07325578 |
| SF-12 questionnaire | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Biobanking with genetic analysis | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Percutaneous procedure in the MSK structures of the pelvis and/or the spine | Procedure | Approved | Bone Tumor | RECRUITING | NCT07325578 |
| SF-12 questionnaire | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Biobanking with genetic analysis | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Percutaneous procedure in the MSK structures of the pelvis and/or the spine | Procedure | Approved | Bone Tumor | RECRUITING | NCT07325578 |
| SF-12 questionnaire | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Biobanking with genetic analysis | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| SF-12 questionnaire | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Biobanking with genetic analysis | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| SF-12 questionnaire | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Biobanking with genetic analysis | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| SF-12 questionnaire | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Biobanking with genetic analysis | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Percutaneous procedure in the MSK structures of the pelvis and/or the spine | Procedure | Approved | Bone Tumor | RECRUITING | NCT07325578 |
| SF-12 questionnaire | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Biobanking with genetic analysis | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Scleral lens wearing keratoconics | Other | Approved | Keratoconus | COMPLETED | NCT03091101 |
| Scleral lens wearing keratoconics | Other | Approved | Keratoconus | COMPLETED | NCT03091101 |
| ClariCore System | Other | Approved | Prostate Cancer | UNKNOWN | NCT02773940 |
| Salkera Emollient Foam | Other | Phase PHASE4 | Keratosis Pilaris | TERMINATED | NCT00944216 |
| Salkera Emollient Foam | Other | Phase PHASE4 | Keratosis Pilaris | TERMINATED | NCT00944216 |
| Phase 2 Wonderlab Product | Other | Approved | Diabetes | COMPLETED | NCT05756712 |
| Phase 2 Placebo | Other | Approved | Diabetes | COMPLETED | NCT05756712 |
| Phase 1 Placebo | Other | Approved | Diabetes | COMPLETED | NCT05756712 |
| Phase 1 Wonderlab Product | Other | Approved | Diabetes | COMPLETED | NCT05756712 |
| Phase 2 Wonderlab Product | Other | Approved | Diabetes | COMPLETED | NCT05756712 |
| Phase 2 Placebo | Other | Approved | Diabetes | COMPLETED | NCT05756712 |
| Phase 1 Placebo | Other | Approved | Diabetes | COMPLETED | NCT05756712 |
| Phase 1 Wonderlab Product | Other | Approved | Diabetes | COMPLETED | NCT05756712 |
| Instant probiotic placebo | Other | Approved | Immunity | COMPLETED | NCT05585021 |
| Wonderlab Kids instant probiotics | Other | Approved | Immunity | COMPLETED | NCT05585021 |
| Instant probiotic placebo | Other | Approved | Immunity | COMPLETED | NCT05585021 |
| Wonderlab Kids instant probiotics | Other | Approved | Immunity | COMPLETED | NCT05585021 |
| MC-1-50 | Other | Phase PHASE1 | B Cell Lymphoma | RECRUITING | NCT06180174 |
| MC-1-50 | Other | Phase PHASE1 | B Cell Lymphoma | RECRUITING | NCT06180174 |
| CD19 and CD22 targeted prime CAR-T cells | Other | Phase PHASE1 | B-ALL | RECRUITING | NCT04781634 |
| CD19 and CD22 targeted prime CAR-T cells | Other | Phase PHASE1 | B-ALL | RECRUITING | NCT04781634 |
| BCMA targeted prime CAR-T cells | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT04776330 |
| BCMA targeted prime CAR-T cells | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT04776330 |
| ChemoFx | Other | Preclinical | Endometrial Cancer | COMPLETED | NCT01049126 |
| DermaTherapy® Linen and underpads. | Drug | Approved | Pressure Ulcers | UNKNOWN | NCT01355666 |
| DermaTherapy® Linen and underpads. | Drug | Approved | Pressure Ulcers | UNKNOWN | NCT01355666 |
| Vehicle | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT01826461 |
| PDI-192 | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT01826461 |
| Placebo DC | Other | Phase PHASE2 | Glioblastoma Multiforme | COMPLETED | NCT01280552 |
| ICT-107 | Other | Phase PHASE2 | Glioblastoma Multiforme | COMPLETED | NCT01280552 |
| Placebo DC | Other | Phase PHASE2 | Glioblastoma Multiforme | COMPLETED | NCT01280552 |
| ICT-107 | Other | Phase PHASE2 | Glioblastoma Multiforme | COMPLETED | NCT01280552 |
| Short Physical Performance Battery | Other | Approved | Aged | COMPLETED | NCT03123757 |
| EQ-5D Survey | Other | Approved | Aged | COMPLETED | NCT03123757 |
| 6 Minute Walk Test | Other | Approved | Aged | COMPLETED | NCT03123757 |
| NPC-1C/NEO-102 | Other | Phase PHASE1 | Metastatic Pancreatic Cancer | COMPLETED | NCT01040000 |
| NPC-1C/NEO-102 | Other | Phase PHASE1 | Metastatic Pancreatic Cancer | COMPLETED | NCT01040000 |
| Cotton Pillowcase | Other | Approved | Acne Vulgaris | COMPLETED | NCT00767104 |
| Silk like Pillowcase | Other | Approved | Acne Vulgaris | COMPLETED | NCT00767104 |
| Cotton Pillowcase | Other | Approved | Acne Vulgaris | COMPLETED | NCT00767104 |
| Silk like Pillowcase | Other | Approved | Acne Vulgaris | COMPLETED | NCT00767104 |
| Anti-NY-ESO-1 TCR transduced T cells | Other | Phase PHASE1 | Lung Cancer, Nonsmall Cell, Recurrent | UNKNOWN | NCT03029273 |
| Cyclophosphamide and Fludarabine | Other | Phase PHASE1 | Lung Cancer, Nonsmall Cell, Recurrent | UNKNOWN | NCT03029273 |
| Anti-NY-ESO-1 TCR transduced T cells | Other | Phase PHASE1 | Lung Cancer, Nonsmall Cell, Recurrent | UNKNOWN | NCT03029273 |
| Cyclophosphamide and Fludarabine | Other | Phase PHASE1 | Lung Cancer, Nonsmall Cell, Recurrent | UNKNOWN | NCT03029273 |
| ClariCore Optical Biopsy System | Other | Approved | Cellular Diagnosis, Prostate Cancer | UNKNOWN | NCT03504761 |
| ClariCore Optical Biopsy System | Other | Approved | Cellular Diagnosis, Prostate Cancer | UNKNOWN | NCT03504761 |
| ClariCore Optical Biopsy System | Other | Approved | Cellular Diagnosis, Prostate Cancer | UNKNOWN | NCT03504761 |
| ClariCore System | Other | Approved | Prostate Cancer | UNKNOWN | NCT02773940 |
| TAEST16001 | Other | Phase PHASE1 | Liver Cancer Stage IV | COMPLETED | NCT03159585 |
| TAEST16001 | Other | Phase PHASE1 | Liver Cancer Stage IV | COMPLETED | NCT03159585 |
| Placebo capsule | Other | Phase PHASE2 | Subjective Sleep Quality | COMPLETED | NCT04167475 |
| Probiotic capsule | Other | Phase PHASE2 | Subjective Sleep Quality | COMPLETED | NCT04167475 |
| Placebo capsule | Other | Phase PHASE2 | Subjective Sleep Quality | COMPLETED | NCT04167475 |
| Probiotic capsule | Other | Phase PHASE2 | Subjective Sleep Quality | COMPLETED | NCT04167475 |
| mobile internet survey on self-test | Other | Preclinical | Susceptibility to Viral and Mycobacterial Infection | COMPLETED | NCT04256395 |
| mobile internet survey on self-test | Other | Preclinical | Susceptibility to Viral and Mycobacterial Infection | COMPLETED | NCT04256395 |
| mobile internet survey on self-test | Other | Preclinical | Susceptibility to Viral and Mycobacterial Infection | COMPLETED | NCT04256395 |
| Questionnaires | Other | Preclinical | Ischemic Heart Disease | COMPLETED | NCT03064360 |
| Patient Activity | Other | Preclinical | Ischemic Heart Disease | COMPLETED | NCT03064360 |
| Laboratory Biomarker Analysis | Other | Preclinical | Ischemic Heart Disease | COMPLETED | NCT03064360 |
| Questionnaires | Other | Preclinical | Ischemic Heart Disease | COMPLETED | NCT03064360 |
| Patient Activity | Other | Preclinical | Ischemic Heart Disease | COMPLETED | NCT03064360 |
| Laboratory Biomarker Analysis | Other | Preclinical | Ischemic Heart Disease | COMPLETED | NCT03064360 |
| Silk-Like Linens | Other | Approved | Pressure Ulcer | COMPLETED | NCT02925741 |
| Silk-Like Linens | Other | Approved | Pressure Ulcer | COMPLETED | NCT02925741 |
| anti-CD19 CAR NK | Other | Phase EARLY_PHASE1 | NHL | UNKNOWN | NCT04639739 |
| anti-CD19 CAR NK | Other | Phase EARLY_PHASE1 | NHL | UNKNOWN | NCT04639739 |
| pCAR-19B cells | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia, in Relapse | UNKNOWN | NCT04888442 |
| pCAR-19B cells | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia, in Relapse | UNKNOWN | NCT04888442 |
| mNGS for pathogen detection | Other | Approved | Encephalitis | COMPLETED | NCT02910037 |
| mNGS for pathogen detection | Other | Approved | Encephalitis | COMPLETED | NCT02910037 |
| Freedom SCS System | Other | Approved | Back Pain | COMPLETED | NCT02514590 |
| Freedom SCS System | Other | Approved | Back Pain | COMPLETED | NCT02514590 |
| Freedom SCS System | Other | Approved | Back Pain | COMPLETED | NCT02514590 |
| pCAR-19B cells | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT04888468 |
| pCAR-19B cells | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | COMPLETED | NCT04888468 |
| Custom Fabricated Splint | Other | Approved | Arthritis | UNKNOWN | NCT05351060 |
| Custom Fabricated Splint | Other | Approved | Arthritis | UNKNOWN | NCT05351060 |
| SF-12 questionnaire | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Biobanking with genetic analysis | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| SF-12 questionnaire | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| Biobanking with genetic analysis | Other | Approved | Chronic Inflammatory Disease | RECRUITING | NCT04334031 |
| liver transplant | Other | Approved | Hepatocellular Carcinoma, Scirrhous | RECRUITING | NCT04499833 |
| liver transplant | Other | Approved | Hepatocellular Carcinoma, Scirrhous | RECRUITING | NCT04499833 |
| CEA-targeted CAR-T cells | Other | Phase PHASE1 | Gastric Cancer | UNKNOWN | NCT05538195 |
| CEA-targeted CAR-T cells | Other | Phase PHASE1 | Gastric Cancer | UNKNOWN | NCT05538195 |
| CEA-targeted CAR-T cells | Other | Phase PHASE1 | Gastric Cancer | UNKNOWN | NCT05538195 |
| Surgical Technical Instructional Video | Other | Approved | Surgical Training | COMPLETED | NCT04404010 |
| Immersive Virtual Reality | Other | Approved | Surgical Training | COMPLETED | NCT04404010 |
| Surgical Technical Instructional Video | Other | Approved | Surgical Training | COMPLETED | NCT04404010 |
| Immersive Virtual Reality | Other | Approved | Surgical Training | COMPLETED | NCT04404010 |
| Placebo | Other | Approved | Low Mood | COMPLETED | NCT04925440 |
| Bifidobacterium longum 1714® strain | Other | Approved | Low Mood | COMPLETED | NCT04925440 |
| Placebo | Other | Approved | Low Mood | COMPLETED | NCT04925440 |
| Bifidobacterium longum 1714® strain | Other | Approved | Low Mood | COMPLETED | NCT04925440 |
| Cyclophosphamide | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma, Relapsed | COMPLETED | NCT04030195 |
| Fludarabine | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma, Relapsed | COMPLETED | NCT04030195 |
| PBCAR20A | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma, Relapsed | COMPLETED | NCT04030195 |
| Ordinary Drink | Other | Approved | Skin Laxity | COMPLETED | NCT05682092 |
| WonderLab Collagen Tripeptide Drink | Other | Approved | Skin Laxity | COMPLETED | NCT05682092 |
| Ordinary Drink | Other | Approved | Skin Laxity | COMPLETED | NCT05682092 |
| WonderLab Collagen Tripeptide Drink | Other | Approved | Skin Laxity | COMPLETED | NCT05682092 |
| TAEST16001 cells | Other | Phase PHASE1 | Soft Tissue Sarcoma | UNKNOWN | NCT04318964 |
| TAEST16001 cells | Other | Phase PHASE1 | Soft Tissue Sarcoma | UNKNOWN | NCT04318964 |
| NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy） | Drug | Phase PHASE1 | Bone Sarcoma | UNKNOWN | NCT03462316 |
| NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy） | Drug | Phase PHASE1 | Bone Sarcoma | UNKNOWN | NCT03462316 |
| C-4-29 Cells | Other | Phase PHASE1 | Multiple Myeloma in Relapse | UNKNOWN | NCT04861480 |
| C-4-29 Cells | Other | Phase PHASE1 | Multiple Myeloma in Relapse | UNKNOWN | NCT04861480 |
| CD19 and CD22 targeted prime CAR- T cells | Other | Phase PHASE1 | B Cell Lymphoma | UNKNOWN | NCT04782193 |
| CD19 and CD22 targeted prime CAR- T cells | Other | Phase PHASE1 | B Cell Lymphoma | UNKNOWN | NCT04782193 |
| CD19 and CD22 targeted CAR-T cells | Other | Phase PHASE1 | Leukemia, B-cell | UNKNOWN | NCT04649983 |
| CD19 and CD22 targeted CAR-T cells | Other | Phase PHASE1 | Leukemia, B-cell | UNKNOWN | NCT04649983 |
| CD19 and CD22 targeted CAR-T cells | Other | Phase PHASE1 | Leukemia, B-cell | UNKNOWN | NCT04648475 |
| CD19 and CD22 targeted CAR-T cells | Other | Phase PHASE1 | Leukemia, B-cell | UNKNOWN | NCT04648475 |
| BCMA CAR-T cells | Other | Phase PHASE1 | Multiple Myeloma | UNKNOWN | NCT04272151 |
| BCMA CAR-T cells | Other | Phase PHASE1 | Multiple Myeloma | UNKNOWN | NCT04272151 |
| CD123 CAR-T cells | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT04272125 |
| CD123 CAR-T cells | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT04272125 |
| CD19 CAR-T cells | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT04271800 |
| CD19 CAR-T cells | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT04271800 |
| CD19 CAR-T cells | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT04271410 |
| CD19 CAR-T cells | Other | Phase PHASE1 | Leukemia | UNKNOWN | NCT04271410 |
| Gynaecological laparoscopic surgery (Sirius System) | Procedure | Approved | Ovarian Cancer | UNKNOWN | NCT05318625 |
| Gynaecological laparoscopic surgery (Sirius System) | Procedure | Approved | Ovarian Cancer | UNKNOWN | NCT05318625 |
| Gynaecological laparoscopic surgery (Sirius System) | Procedure | Approved | Ovarian Cancer | UNKNOWN | NCT05318625 |
| CD70 CAR-T cells | Other | Phase PHASE1 | Metastatic Tumor | UNKNOWN | NCT05468190 |
| CD70 CAR-T cells | Other | Phase PHASE1 | Metastatic Tumor | UNKNOWN | NCT05468190 |
| CD70 CAR-T cells | Other | Phase PHASE1 | Metastatic Tumor | UNKNOWN | NCT05420545 |
| CD70 CAR-T cells | Other | Phase PHASE1 | Metastatic Tumor | UNKNOWN | NCT05420545 |
| CD123 targeted CAR-NK cells | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT06006403 |
| CD123 targeted CAR-NK cells | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT06006403 |
| CEA-targeted CAR-T cells | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT06043466 |
| CEA-targeted CAR-T cells | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT06043466 |
| CEA-targeted CAR-T cells | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT06043466 |
| Nirogacestat | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT04171843 |
| Cyclophosphamide | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT04171843 |
| Fludarabine | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT04171843 |
| PBCAR269A | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT04171843 |
| CD19 targeted CAR-T cells | Other | Phase PHASE1 | SLE (Systemic Lupus) | RECRUITING | NCT06056921 |
| CD19 targeted CAR-T cells | Other | Phase PHASE1 | SLE (Systemic Lupus) | RECRUITING | NCT06056921 |
| CD19 targeted CAR-T cells | Other | Phase PHASE1 | SLE (Systemic Lupus) | RECRUITING | NCT06056921 |
| CD70 CAR-T cells | Other | Phase PHASE1 | Renal Cell Carcinoma | RECRUITING | NCT06010875 |
| CD70 CAR-T cells | Other | Phase PHASE1 | Renal Cell Carcinoma | RECRUITING | NCT06010875 |
| CD70 CAR-T cells | Other | Phase PHASE1 | Renal Cell Carcinoma | RECRUITING | NCT06010875 |
| CEA CAR-T cells | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT06010862 |
| CEA CAR-T cells | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT06010862 |
| CEA CAR-T cells | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT06010862 |
| CEA-targeted CAR-T cells | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT06126406 |
| CEA-targeted CAR-T cells | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT06126406 |
| CEA-targeted CAR-T cells | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT06126406 |
| Gynaecological laparoscopic surgery (Sirius System) | Procedure | Approved | Ovarian Cancer | UNKNOWN | NCT05048407 |
| Gynaecological laparoscopic surgery (Sirius System) | Procedure | Approved | Ovarian Cancer | UNKNOWN | NCT05048407 |
| Gynaecological laparoscopic surgery (Sirius System) | Procedure | Approved | Ovarian Cancer | UNKNOWN | NCT05048407 |
| Placebo product | Other | Approved | IBS - Irritable Bowel Syndrome | COMPLETED | NCT05900752 |
| QiMeiYan Probiotics | Other | Approved | IBS - Irritable Bowel Syndrome | COMPLETED | NCT05900752 |
| Placebo product | Other | Approved | IBS - Irritable Bowel Syndrome | COMPLETED | NCT05900752 |
| QiMeiYan Probiotics | Other | Approved | IBS - Irritable Bowel Syndrome | COMPLETED | NCT05900752 |
| Study product D | Other | Approved | Overweight | COMPLETED | NCT05710055 |
| Study product C (Wonderlab wonder4shape) | Other | Approved | Overweight | COMPLETED | NCT05710055 |
| Study product B (Wonderlab wonder4shape) | Other | Approved | Overweight | COMPLETED | NCT05710055 |
| Study product A (Wonderlab wonder4shape) | Other | Approved | Overweight | COMPLETED | NCT05710055 |
| Study product D | Other | Approved | Overweight | COMPLETED | NCT05710055 |
| Study product C (Wonderlab wonder4shape) | Other | Approved | Overweight | COMPLETED | NCT05710055 |
| Study product B (Wonderlab wonder4shape) | Other | Approved | Overweight | COMPLETED | NCT05710055 |
| Study product A (Wonderlab wonder4shape) | Other | Approved | Overweight | COMPLETED | NCT05710055 |
| Ordinary Drink | Other | Approved | Skin Darken | COMPLETED | NCT05696938 |
| Wonderlab Nicotinamide Drink | Other | Approved | Skin Darken | COMPLETED | NCT05696938 |
| Ordinary Drink | Other | Approved | Skin Darken | COMPLETED | NCT05696938 |
| Wonderlab Nicotinamide Drink | Other | Approved | Skin Darken | COMPLETED | NCT05696938 |
| NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy) | Drug | Phase PHASE2 | Soft Tissue Sarcoma | UNKNOWN | NCT05549921 |
| NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy) | Drug | Phase PHASE2 | Soft Tissue Sarcoma | UNKNOWN | NCT05549921 |
| MC-1-50 | Other | Phase PHASE1 | B Cell Lymphoma | RECRUITING | NCT06180174 |
| CAR-T cells | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | UNKNOWN | NCT05420493 |
| CAR-T cells | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | UNKNOWN | NCT05420493 |
| CAR-T cells | Other | Phase PHASE1 | Relapsed Non-Hodgkin Lymphoma | UNKNOWN | NCT05420493 |
| CEA CAR-T cells | Other | Phase PHASE1 | Colorectal Cancer | UNKNOWN | NCT05415475 |
| CEA CAR-T cells | Other | Phase PHASE1 | Colorectal Cancer | UNKNOWN | NCT05415475 |
| CD70 CAR-T cells | Other | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT06215950 |
| CD70 CAR-T cells | Other | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT06215950 |
| Optical coherence tomography | Other | Preclinical | Optical Coherence Tomography | COMPLETED | NCT05517889 |
| Optical coherence tomography | Other | Preclinical | Optical Coherence Tomography | COMPLETED | NCT05517889 |
| Study product C (placebo) | Other | Approved | Overweight and Obesity | COMPLETED | NCT06030999 |
| Study product B (Wonderlab wonder4shape) | Other | Approved | Overweight and Obesity | COMPLETED | NCT06030999 |
| Study product A (Wonderlab wonder4shape) | Other | Approved | Overweight and Obesity | COMPLETED | NCT06030999 |
| Study product C (placebo) | Other | Approved | Overweight and Obesity | COMPLETED | NCT06030999 |
| Study product B (Wonderlab wonder4shape) | Other | Approved | Overweight and Obesity | COMPLETED | NCT06030999 |
| Study product A (Wonderlab wonder4shape) | Other | Approved | Overweight and Obesity | COMPLETED | NCT06030999 |
| Placebo | Other | Phase PHASE3 | Glioblastoma Multiforme | SUSPENDED | NCT02546102 |
| ICT-107 | Other | Phase PHASE3 | Glioblastoma Multiforme | SUSPENDED | NCT02546102 |
| Placebo | Other | Phase PHASE3 | Glioblastoma Multiforme | SUSPENDED | NCT02546102 |
| ICT-107 | Other | Phase PHASE3 | Glioblastoma Multiforme | SUSPENDED | NCT02546102 |
| Physical examination and Questionnaires | Other | Preclinical | Diabetes | COMPLETED | NCT05717491 |
| Biological analysis, Physical examination and Questionnaires | Other | Preclinical | Diabetes | COMPLETED | NCT05717491 |
| Physical examination and Questionnaires | Other | Preclinical | Diabetes | COMPLETED | NCT05717491 |
| Biological analysis, Physical examination and Questionnaires | Other | Preclinical | Diabetes | COMPLETED | NCT05717491 |
| Placebo | Other | Phase PHASE2 | Treatment Resistant Depression | COMPLETED | NCT05414422 |
| PCN-101 | Other | Phase PHASE2 | Treatment Resistant Depression | COMPLETED | NCT05414422 |
| Breast Cancer, Cardiometabolic, Cardiovascular Risk Screening and Follow up | Other | Preclinical | Breast Cancer Risk | NOT_YET_RECRUITING | NCT05848856 |
| Breast Cancer, Cardiometabolic, Cardiovascular Risk Screening and Follow up | Other | Preclinical | Breast Cancer Risk | NOT_YET_RECRUITING | NCT05848856 |
| PBCAR19B | Other | Phase PHASE1 | CD19 Expressing Malignancies | COMPLETED | NCT04649112 |
| pCAR-19B cells | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | RECRUITING | NCT05334823 |
| pCAR-19B cells | Other | Phase PHASE2 | Acute Lymphoblastic Leukemia | RECRUITING | NCT05334823 |
| CEA-targeted CAR-T cells | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT06006390 |
| CEA-targeted CAR-T cells | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT06006390 |
| RUC-4 Compound | Other | Phase PHASE1 | Coronary Disease | COMPLETED | NCT03844191 |
| atezolizumab | Other | Phase PHASE1 | Malignant Melanoma | COMPLETED | NCT04123470 |
| delolimogene mupadenorepvec | Other | Phase PHASE1 | Malignant Melanoma | COMPLETED | NCT04123470 |
| atezolizumab | Other | Phase PHASE1 | Malignant Melanoma | COMPLETED | NCT04123470 |
| delolimogene mupadenorepvec | Other | Phase PHASE1 | Malignant Melanoma | COMPLETED | NCT04123470 |
| atezolizumab | Other | Phase PHASE1 | Malignant Melanoma | COMPLETED | NCT04123470 |
| delolimogene mupadenorepvec | Other | Phase PHASE1 | Malignant Melanoma | COMPLETED | NCT04123470 |
| [11C]CPPC Injection | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT04749433 |
| [11C]CPPC Injection | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT04749433 |
| MC-1-50 | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia, in Relapse | NOT_YET_RECRUITING | NCT06641024 |
| MC-1-50 | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia, in Relapse | NOT_YET_RECRUITING | NCT06641024 |
| Anti-CD19 UCAR-T cells | Other | Phase PHASE1 | Dermatomyositis, Juvenile | RECRUITING | NCT06686524 |
| Anti-CD19 UCAR-T cells | Other | Phase PHASE1 | Dermatomyositis, Juvenile | RECRUITING | NCT06686524 |
| Anti-CD123 CAR NK cells | Other | Phase PHASE1 | AML (Acute Myeloid Leukemia) | RECRUITING | NCT06690827 |
| Anti-CD123 CAR NK cells | Other | Phase PHASE1 | AML (Acute Myeloid Leukemia) | RECRUITING | NCT06690827 |
| Standardized assessments and biobanking | Other | Preclinical | Decompensated Liver Cirrhosis | NOT_YET_RECRUITING | NCT06723275 |
| Standardized assessments, guided tumor biopsy and biobanking | Other | Preclinical | Decompensated Liver Cirrhosis | NOT_YET_RECRUITING | NCT06723275 |
| Standardized assessments and biobanking | Other | Preclinical | Decompensated Liver Cirrhosis | NOT_YET_RECRUITING | NCT06723275 |
| Standardized assessments, guided tumor biopsy and biobanking | Other | Preclinical | Decompensated Liver Cirrhosis | NOT_YET_RECRUITING | NCT06723275 |
| Targeted CEA CAR-T | Other | Phase PHASE1 | Advanced Lung Cancer | RECRUITING | NCT06768151 |
| Targeted CEA CAR-T | Other | Phase PHASE1 | Advanced Lung Cancer | RECRUITING | NCT06768151 |
| donor-derived NK cell infusion | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT04616209 |
| donor-derived NK cell infusion | Other | Phase PHASE1 | Non-small Cell Lung Cancer | RECRUITING | NCT04616209 |
| BCMA CAR-T cells | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT04271644 |
| BCMA CAR-T cells | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT04271644 |
| Community Health Worker Support | Other | Approved | Cancer | COMPLETED | NCT04843332 |
| Community Health Worker Support | Other | Approved | Cancer | COMPLETED | NCT04843332 |
| Anti-CD5 CAR NK cells | Other | Phase PHASE1 | T-ALL/Lymphoma | RECRUITING | NCT06909474 |
| Anti-CD5 CAR NK cells | Other | Phase PHASE1 | T-ALL/Lymphoma | RECRUITING | NCT06909474 |
| Targeted CEA CAR-T | Other | Phase PHASE1 | Advanced Lung Cancer | RECRUITING | NCT06903117 |
| Targeted CEA CAR-T | Other | Phase PHASE1 | Advanced Lung Cancer | RECRUITING | NCT06903117 |
| GCAR1 | Other | Phase EARLY_PHASE1 | Sarcoma | ACTIVE_NOT_RECRUITING | NCT06813417 |
| GCAR1 | Other | Phase EARLY_PHASE1 | Sarcoma | ACTIVE_NOT_RECRUITING | NCT06813417 |
| CEA CAR-T cells | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT05396300 |
| NEO-201 in combination with pembrolizumab | Other | Phase PHASE1 | Non Small Cell Lung Cancer | RECRUITING | NCT03476681 |
| NEO-201 in combination with pembrolizumab | Other | Phase PHASE1 | Non Small Cell Lung Cancer | RECRUITING | NCT03476681 |
| anti-BCMA/CD70-CAR-T cells | Other | Phase PHASE1 | CAR T Cell Therapy | RECRUITING | NCT06934447 |
| anti-BCMA/CD70-CAR-T cells | Other | Phase PHASE1 | CAR T Cell Therapy | RECRUITING | NCT06934447 |
| NPC-1C | Other | Phase PHASE1 | Pancreatic Cancer, Adult | TERMINATED | NCT01834235 |
| nab-paclitaxel | Other | Phase PHASE1 | Pancreatic Cancer, Adult | TERMINATED | NCT01834235 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Cancer, Adult | TERMINATED | NCT01834235 |
| NPC-1C | Other | Phase PHASE1 | Pancreatic Cancer, Adult | TERMINATED | NCT01834235 |
| nab-paclitaxel | Other | Phase PHASE1 | Pancreatic Cancer, Adult | TERMINATED | NCT01834235 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Cancer, Adult | TERMINATED | NCT01834235 |
| Targeted CEA CAR-T | Other | Phase PHASE1 | Advanced Lung Cancer | RECRUITING | NCT06992583 |
| Targeted CEA CAR-T | Other | Phase PHASE1 | Advanced Lung Cancer | RECRUITING | NCT06992583 |
| Blood test: ClarityDX Prostate | Other | Preclinical | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT03957252 |
| Blood test: ClarityDX Prostate | Other | Preclinical | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT03957252 |
| CD70 CAR-T cells | Other | Phase PHASE1 | Metastatic Tumor | RECRUITING | NCT05518253 |
| CD70 CAR-T cells | Other | Phase PHASE1 | Metastatic Tumor | RECRUITING | NCT05518253 |
| Targeted CEA CAR-T | Other | Phase PHASE1 | Advanced Lung Cancer | RECRUITING | NCT06945523 |
| Targeted CEA CAR-T | Other | Phase PHASE1 | Advanced Lung Cancer | RECRUITING | NCT06945523 |
| Targeted CEA CAR-T | Other | Phase PHASE1 | Advanced Lung Cancer | RECRUITING | NCT06945523 |
| Trio Whole Genome Sequencing and Participant-Specific Research | Other | Preclinical | Rare Diseases | RECRUITING | NCT04586075 |
| Trio Whole Genome Sequencing and Participant-Specific Research | Other | Preclinical | Rare Diseases | RECRUITING | NCT04586075 |
| CMV-VST | Other | Approved | Cytomegalovirus Viremia | ACTIVE_NOT_RECRUITING | NCT07015801 |
| CMV-VST | Other | Approved | Cytomegalovirus Viremia | ACTIVE_NOT_RECRUITING | NCT07015801 |
| Active Control | Other | Approved | Depressive Symptoms | WITHDRAWN | NCT04815681 |
| Common Elements Toolbox | Other | Approved | Depressive Symptoms | WITHDRAWN | NCT04815681 |
| Active Control | Other | Approved | Depressive Symptoms | WITHDRAWN | NCT04815681 |
| Common Elements Toolbox | Other | Approved | Depressive Symptoms | WITHDRAWN | NCT04815681 |
| OPM-101 | Other | Phase PHASE1 | Advanced Melanoma | NOT_YET_RECRUITING | NCT07040436 |
| OPM-101 | Other | Phase PHASE1 | Advanced Melanoma | NOT_YET_RECRUITING | NCT07040436 |
| 18F fluciclovine | Other | Phase PHASE2 | Brain Metastases | COMPLETED | NCT04410367 |
| Oral Medicine Consultation Visit/Sample Collection | Other | Preclinical | Oropharyngeal Squamous Cell Carcinoma | WITHDRAWN | NCT06362421 |
| Pre-Study Visit | Other | Preclinical | Oropharyngeal Squamous Cell Carcinoma | WITHDRAWN | NCT06362421 |
| Pre-Radiation Dental Evaluation/Sample Collection | Other | Preclinical | Oropharyngeal Squamous Cell Carcinoma | WITHDRAWN | NCT06362421 |
| Oral Medicine Consultation Visit/Sample Collection | Other | Preclinical | Oropharyngeal Squamous Cell Carcinoma | WITHDRAWN | NCT06362421 |
| Pre-Study Visit | Other | Preclinical | Oropharyngeal Squamous Cell Carcinoma | WITHDRAWN | NCT06362421 |
| Pre-Radiation Dental Evaluation/Sample Collection | Other | Preclinical | Oropharyngeal Squamous Cell Carcinoma | WITHDRAWN | NCT06362421 |
| Oral Medicine Consultation Visit/Sample Collection | Other | Preclinical | Oropharyngeal Squamous Cell Carcinoma | WITHDRAWN | NCT06362421 |
| Pre-Study Visit | Other | Preclinical | Oropharyngeal Squamous Cell Carcinoma | WITHDRAWN | NCT06362421 |
| Pre-Radiation Dental Evaluation/Sample Collection | Other | Preclinical | Oropharyngeal Squamous Cell Carcinoma | WITHDRAWN | NCT06362421 |
| Atorvastatin Oral Tablet | Other | Phase PHASE2 | Mild Cognitive Impairment | RECRUITING | NCT04765137 |
| Atorvastatin Oral Tablet | Other | Phase PHASE2 | Mild Cognitive Impairment | RECRUITING | NCT04765137 |
| 18F fluciclovine | Other | Phase PHASE3 | Brain Metastases | COMPLETED | NCT04410133 |
| H2 Receptor Antagonist | Other | Phase PHASE1 | Solid Tumours | RECRUITING | NCT06789172 |
| Fed | Other | Phase PHASE1 | Solid Tumours | RECRUITING | NCT06789172 |
| Fasting | Other | Phase PHASE1 | Solid Tumours | RECRUITING | NCT06789172 |
| Pembrolizumab | Other | Phase PHASE1 | Solid Tumours | RECRUITING | NCT06789172 |
| OKN4395 | Other | Phase PHASE1 | Solid Tumours | RECRUITING | NCT06789172 |
| CD19 CAR-T cells | Other | Phase PHASE1 | Autoimmune Diseases | NOT_YET_RECRUITING | NCT07161193 |
| CD19 CAR-T cells | Other | Phase PHASE1 | Autoimmune Diseases | NOT_YET_RECRUITING | NCT07161193 |
| BCMA/CD70-targetd CAR-T | Other | Phase PHASE1 | Juvenile Dermatomyositis (JDM) | RECRUITING | NCT07184450 |
| BCMA/CD70-targetd CAR-T | Other | Phase PHASE1 | Juvenile Dermatomyositis (JDM) | RECRUITING | NCT07184450 |
| anti-CD19-CAR-T cells | Other | Phase PHASE1 | Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT06222853 |
| anti-CD19-CAR-T cells | Other | Phase PHASE1 | Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT06222853 |
| anti-CD19-CAR-T cells | Other | Phase PHASE1 | Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT06222853 |
| External Facilitation | Other | Preclinical | Tobacco Dependence Treatment | NOT_YET_RECRUITING | NCT06745258 |
| External Facilitation | Other | Preclinical | Tobacco Dependence Treatment | NOT_YET_RECRUITING | NCT06745258 |
| PBGENE-HBV | Other | Phase PHASE1 | HEPATITIS B CHRONIC | RECRUITING | NCT06680232 |
| CD70-targeted CAR-T cells | Other | Phase PHASE1 | Renal Cell Carcinoma (RCC) | RECRUITING | NCT07181720 |
| CD70-targeted CAR-T cells | Other | Phase PHASE1 | Renal Cell Carcinoma (RCC) | RECRUITING | NCT07181720 |
| Invivo CAR-T | Other | Phase PHASE1 | B-Acute Lymphoblastic Leukemia | RECRUITING | NCT07239323 |
| Invivo CAR-T | Other | Phase PHASE1 | B-Acute Lymphoblastic Leukemia | RECRUITING | NCT07239323 |
| CEA-targeted CAR-T cells | Other | Phase PHASE1 | Peritoneal Metastases From Colorectal Cancer | RECRUITING | NCT07247396 |
| CEA-targeted CAR-T cells | Other | Phase PHASE1 | Peritoneal Metastases From Colorectal Cancer | RECRUITING | NCT07247396 |
| PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib | Other | Phase PHASE1 | Non-small Cell Lung Cancer | COMPLETED | NCT07271446 |
| PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib | Other | Phase PHASE1 | Non-small Cell Lung Cancer | COMPLETED | NCT07271446 |
| MC-1-50 | Other | Phase PHASE1 | Systemic Lupus Erythematosus (SLE) | RECRUITING | NCT06892145 |
| MC-1-50 | Other | Phase PHASE1 | Systemic Lupus Erythematosus (SLE) | RECRUITING | NCT06892145 |
| MC-1-50 | Other | Phase PHASE1 | Systemic Lupus Erythematosus (SLE) | RECRUITING | NCT06892145 |
| Intraperitoneal infusion of FAST CEA-targeted CAR-T | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT06821048 |
| Intraperitoneal infusion of FAST CEA-targeted CAR-T | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT06821048 |
| Norepinephrine and Vasopressin for Rescue | Other | Phase PHASE3 | Septic Shock | RECRUITING | NCT06464510 |
| Early Vasopressin | Other | Phase PHASE3 | Septic Shock | RECRUITING | NCT06464510 |
| Norepinephrine and Vasopressin for Rescue | Other | Phase PHASE3 | Septic Shock | RECRUITING | NCT06464510 |
| Early Vasopressin | Other | Phase PHASE3 | Septic Shock | RECRUITING | NCT06464510 |
| BCMA/CD70 CAR-T cells | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT07318259 |
| BCMA/CD70 CAR-T cells | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT07318259 |
| PTOC1 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT07403097 |
| PTOC1 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | RECRUITING | NCT07403097 |
| PIC1 Injection | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | RECRUITING | NCT07456371 |
| PIC1 Injection | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | RECRUITING | NCT07456371 |
| Pain Education | Other | Approved | Chronic Pancreatitis | COMPLETED | NCT03707431 |
| Web-based CBT | Other | Approved | Chronic Pancreatitis | COMPLETED | NCT03707431 |
| Pain Education | Other | Approved | Chronic Pancreatitis | COMPLETED | NCT03707431 |
| Web-based CBT | Other | Approved | Chronic Pancreatitis | COMPLETED | NCT03707431 |
| Percutaneous procedure in the MSK structures of the pelvis and/or the spine | Procedure | Approved | Bone Tumor | NOT_YET_RECRUITING | NCT07325578 |
| Percutaneous procedure in the MSK structures of the pelvis and/or the spine | Procedure | Approved | Bone Tumor | NOT_YET_RECRUITING | NCT07325578 |
| BGM-2121 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07346846 |
| BGM-2121 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07346846 |
| BGM-2121 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07346846 |
| PBGENE-HBV | Other | Preclinical | Chronic HBV Infection | ENROLLING_BY_INVITATION | NCT07254208 |
| Educational program | Other | Preclinical | Overweight, Infant | ACTIVE_NOT_RECRUITING | NCT05121090 |
| Educational program | Other | Preclinical | Overweight, Infant | ACTIVE_NOT_RECRUITING | NCT05121090 |
| Educational program | Other | Preclinical | Overweight, Infant | ACTIVE_NOT_RECRUITING | NCT05121090 |
| PBGENE-DMD (IV) | Other | Phase PHASE1 | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | RECRUITING | NCT07429240 |
| PBGENE-DMD (IV) | Other | Phase PHASE1 | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | RECRUITING | NCT07429240 |
| PBGENE-DMD (IV) | Other | Phase PHASE1 | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | RECRUITING | NCT07429240 |
| PBGENE-DMD (IV) | Other | Phase PHASE1 | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | RECRUITING | NCT07429240 |
| PBGENE-DMD (IV) | Other | Phase PHASE1 | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | RECRUITING | NCT07429240 |
| PBGENE-DMD (IV) | Other | Phase PHASE1 | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | RECRUITING | NCT07429240 |
| PBGENE-DMD (IV) | Other | Phase PHASE1 | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | RECRUITING | NCT07429240 |
| CEA CAR-T cells | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05396300 |
| Intraperitoneal infusion of FAST CEA-targeted CAR-T | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05396300 |
| CEA CAR-T cells | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05396300 |
| Intraperitoneal infusion of FAST CEA-targeted CAR-T | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05396300 |
| CEA CAR-T cells | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05396300 |
| Intraperitoneal infusion of FAST CEA-targeted CAR-T | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05396300 |
| CEA CAR-T cells | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05396300 |
| Intraperitoneal infusion of FAST CEA-targeted CAR-T | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05396300 |
| CEA CAR-T cells | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05396300 |
| Intraperitoneal infusion of FAST CEA-targeted CAR-T | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05396300 |
| CEA CAR-T cells | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05396300 |
| Intraperitoneal infusion of FAST CEA-targeted CAR-T | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05396300 |
| CEA CAR-T cells | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05396300 |
| Intraperitoneal infusion of FAST CEA-targeted CAR-T | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05396300 |
| CEA CAR-T cells | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05396300 |
| Intraperitoneal infusion of FAST CEA-targeted CAR-T | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05396300 |
| CEA CAR-T cells | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05396300 |
| Intraperitoneal infusion of FAST CEA-targeted CAR-T | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05396300 |
| PBGENE-HBV | Other | Preclinical | Chronic HBV Infection | ENROLLING_BY_INVITATION | NCT07254208 |
| Educational program | Other | Preclinical | Overweight, Infant | ACTIVE_NOT_RECRUITING | NCT05121090 |
| Educational program | Other | Preclinical | Overweight, Infant | ACTIVE_NOT_RECRUITING | NCT05121090 |
| Educational program | Other | Preclinical | Overweight, Infant | ACTIVE_NOT_RECRUITING | NCT05121090 |
| PBGENE-HBV | Other | Preclinical | Chronic HBV Infection | ENROLLING_BY_INVITATION | NCT07254208 |
| Educational program | Other | Preclinical | Overweight, Infant | ACTIVE_NOT_RECRUITING | NCT05121090 |
| PBGENE-HBV | Other | Preclinical | Chronic HBV Infection | ENROLLING_BY_INVITATION | NCT07254208 |
| Educational program | Other | Preclinical | Overweight, Infant | ACTIVE_NOT_RECRUITING | NCT05121090 |
| PBGENE-HBV | Other | Preclinical | Chronic HBV Infection | ENROLLING_BY_INVITATION | NCT07254208 |
| Educational program | Other | Preclinical | Overweight, Infant | ACTIVE_NOT_RECRUITING | NCT05121090 |
| PBGENE-HBV | Other | Preclinical | Chronic HBV Infection | ENROLLING_BY_INVITATION | NCT07254208 |
| BGM-2121 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07346846 |
| Educational program | Other | Preclinical | Overweight, Infant | ACTIVE_NOT_RECRUITING | NCT05121090 |
| PBGENE-HBV | Other | Preclinical | Chronic HBV Infection | ENROLLING_BY_INVITATION | NCT07254208 |
| BGM-2121 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07346846 |
| Educational program | Other | Preclinical | Overweight, Infant | ACTIVE_NOT_RECRUITING | NCT05121090 |
| PBGENE-HBV | Other | Preclinical | Chronic HBV Infection | ENROLLING_BY_INVITATION | NCT07254208 |
| BGM-2121 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07346846 |
| BGM-2121 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07346846 |
| BGM-2121 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07346846 |
| BGM-2121 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07346846 |
| NPC-1C/NEO-102 | DRUG | Phase PHASE1 | Metastatic Pancreatic Cancer | COMPLETED | NCT01040000 |
| mNGS for pathogen detection | DEVICE | Approved | Encephalitis | COMPLETED | NCT02910037 |
| NEO-201 in combination with pembrolizumab | DRUG | Phase PHASE1 | Non Small Cell Lung Cancer | RECRUITING | NCT03476681 |
| NPC-1C | DRUG | Phase PHASE1 | Pancreatic Cancer, Adult | TERMINATED | NCT01834235 |
| nab-paclitaxel | DRUG | Phase PHASE1 | Pancreatic Cancer, Adult | TERMINATED | NCT01834235 |
| Gemcitabine | DRUG | Phase PHASE1 | Pancreatic Cancer, Adult | TERMINATED | NCT01834235 |
| CD19 CAR-T cells | BIOLOGICAL | Phase PHASE1 | Autoimmune Diseases | NOT_YET_RECRUITING | NCT07161193 |
| Educational program | BEHAVIORAL | Preclinical | Overweight, Infant | RECRUITING | NCT05121090 |
| PBGENE-DMD (IV) | BIOLOGICAL | Phase PHASE1 | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | NOT_YET_RECRUITING | NCT07429240 |
| PBGENE-HBV | BIOLOGICAL | Preclinical | Chronic HBV Infection | NOT_YET_RECRUITING | NCT07254208 |
| PBCAR19B | GENETIC | Phase PHASE1 | CD19 Expressing Malignancies | COMPLETED | NCT04649112 |
| Nirogacestat | DRUG | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT04171843 |
| PBCAR269A | GENETIC | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT04171843 |
| Cyclophosphamide | DRUG | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT04171843 |
| Fludarabine | DRUG | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT04171843 |
| PBCAR20A | GENETIC | Phase PHASE1 | Non-Hodgkin's Lymphoma, Relapsed | COMPLETED | NCT04030195 |
Total products: 442